

CELGENE CORP /DE/  
Form 8-K  
January 11, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 11, 2016

**CELGENE CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware                      001-34912                      22-2711928  
(State or other jurisdiction of      (Commission File Number) (IRS Employer Identification No.)  
incorporation)

86 Morris Avenue, Summit, New Jersey 07901  
(Address of principal executive offices)      (Zip Code)

Registrant's telephone number, including area code: (908) 673-9000

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

Celgene Corporation (the “Company”) today announced organizational changes that will position the Company for continued long-term growth. Effective March 1, 2016:

· Bob Hugin to serve as Executive Chairman. Bob Hugin will continue to lead the Board of Directors and manage the strategic direction of the Company.

- Mark Alles will be promoted to Chief Executive Officer (CEO).
- Jacquelyn Fouse, PhD, will be promoted to President and Chief Operating Officer (COO).
- Scott Smith, President Immunology & Inflammation, will assume an expanded leadership role.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibit 99.1 Press Release dated January 11, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: January 11, 2016 By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President  
Chief Financial Officer  
(principal financial and accounting officer)

EXHIBIT INDEX

**Exhibit No. Description**

99.1 Press Release dated January 11, 2016 announcing certain management changes.